Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;26(3):307-320.
doi: 10.1007/s40257-025-00928-w. Epub 2025 Feb 21.

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review

Dahyeon Kim  1 , Seanna Yang  2 , Minka Gill  3 , Nickoulet Babaei  1 , Mireya Cervantes  4 , Jashin J Wu  5
Affiliations
Review

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review

Dahyeon Kim et al. Am J Clin Dermatol. 2025 May.

Abstract

Innovations in biologics are transforming the treatment of psoriatic diseases. The ability to target specific levels of immune activation provides a distinct advantage. Interleukin (IL)-17 inhibitors fall into this class of biologics, and they are effectively used to treat a spectrum of psoriatic diseases, such as psoriasis vulgaris and psoriatic arthritis. In recent years, anti-IL-17 agents have been the focus of therapeutic development, with various formulations and routes of administration. In this manuscript, we review pipeline anti-IL-17 therapies for psoriatic diseases identified through a search of ClinicalTrials.gov (January 2019-December 2024) and other databases. Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: None was received. Conflicts of interest: Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Codex Labs, Dermavant, DermTech, Dr. Reddy's Laboratories, Eli Lilly, EPI Health, Galderma, Incyte, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health. No conflicts of interest for Dahyeon Kim, Seanna Yang, Minka Gill, Nickoulet Babaei, and Mireya Cervantes. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Availability of data and material: Not applicable. Code availability: Not applicable. Author contributions: All listed authors had substantial contributions to the design of the work and to its review, approve of its final version, and agree to be accountable for all aspects. All authors read and approved the final version.

References

    1. Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21:170–3. https://doi.org/10.7861/clinmed.2021-0257 . - DOI
    1. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386:983–94. https://doi.org/10.1016/S0140-6736(14)61909-7 . - DOI - PubMed
    1. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol. 2017;76:377–90. https://doi.org/10.1016/j.jaad.2016.07.064 . - DOI - PubMed - PMC
    1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416–22. https://doi.org/10.1097/BOR.0b013e3283031c99 . - DOI - PubMed - PMC
    1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475. https://doi.org/10.3390/ijms20061475 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources